[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365515-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365515-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","diffinvex-identifies-evolutionary-shifts-in-driver-gene-repertoires-during-tumorigenesis-and-chemotherapy","DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy","","DiffInvex is developed to identify changes in selection acting on individual genes in somatic genomes during tumorigenesis and chemotherapy. The framework uses an empirical mutation-rate baseline derived from non-coding DNA to account for shifts in neutral mutagenesis during cancer evolution. Applied to 11,000+ whole-genome sequences across ~30 cancer types and tissues, it finds genes under conditional positive or negative selection tied to specific chemotherapeutics, supporting drug-resistance mechanisms and matching gene–chemotherapy associations via functional impacts before versus after therapy, replicated in independent studies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/diffinvex-identifies-evolutionary-shifts-in-driver-gene-repertoires-during-tumorigenesis-and-chemotherapy/365515/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/diffinvex-identifies-evolutionary-shifts-in-driver-gene-repertoires-during-tumorigenesis-and-chemotherapy/365515.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does DiffInvex address in cancer genomics?","Question",{"text":63,"@type":64},"It quantifies conditional selection on individual genes across different conditions, handling shifts in neutral mutagenesis that complicate causal identification of chemotherapy-resistance mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does DiffInvex correct for changes in background mutation rates?",{"text":68,"@type":64},"It uses an empirical local mutation-rate baseline from non-coding DNA to track neutral mutagenesis changes across cancer evolution, reducing reliance on proxy covariates like replication timing or gene expression.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study find when DiffInvex is applied to whole-genome sequences?",{"text":72,"@type":64},"It identifies treatment-associated selection in 11 genes across different chemotherapy classes, links selected mutations in specific genes with drug exposure, and supports associations using pre- versus post-therapy functional impacts replicated in independent studies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365515,1790644902,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-025-59397-8](https://doi.org/10.1038/s41467-025-59397-8)  \nDiffInvex identiﬁes evolutionary shifts in drivergene repertoires duringtumorigenesis and chemotherapy  \nReceived: 7 August 2024  \n\n| Accepted: 22 April 2025 |\n| --- |\n| |\n| Check for updates |\n\nAhmed Khalil 1 & Fran Supek 1,2,3   \nSomatic cells can transform into tumors due to mutations, and the tumors further evolve towards increased aggressiveness and therapy resistance. We develop DiffInvex, a framework for identifying changes in selection acting on individual genes in somatic genomes, drawing on an empirical mutation rate baseline derived from non-coding DNA that accounts for shifts in neutral mutagenesis during cancer evolution. We apply DiffInvex to >11,000 somatic whole-genome sequences from ~30 cancer types or healthy tissues, identifying genes where point mutations are under conditional positive or negative selection during exposure to speciﬁc chemotherapeutics, suggesting drug resistance mechanisms occurring via point mutation. DiffInvex identiﬁes 11 genes exhibiting treatment-associated selection for different classes of chemotherapies, linking selected mutations in PIK3CA, APC, MAP2K4, SMAD4, STK11 and MAP3K1 with drug exposure. Various gene-chemotherapy associations are further supported by differential functional impact of mutations preversus post-therapy, and are also replicated in independent studies. In addition to nominating drug resistance genes, we contrast the genomes of healthy versus cancerous cells of matched human tissues. We identify noncancerous expansion-speciﬁc drivers, including NOTCH1 and ARID1A. DiffInvex can also be applied to diverse analyses in cancer evolution to identify changes in driver gene repertoires across time or space.  \nThe somatic genome accumulates driver mutations, evolving from healthy cells to early-stage tumors, and further towards late-stage malignancies, which progress towards higher aggressiveness. One important aspect of the latter is gaining the ability to resist chemotherapy, a standard treatment for cancer, where multiple drugs are typically used in combination, supplemented with immunotherapy or radiotherapy to kill rapidly dividing cancer cells. However, the surviving cells typically give rise to resistant tumors rather than being an exception. This poses a signiﬁcant challenge in cancer treatment: tumors often show good initial response to chemotherapy, but later relapse1,2, indicating that some genetic or epigenetic  \nfeatures have evolved to grant tumor cells resistance. Identifying these changes and understanding the underlying mechanisms is the ﬁrst step toward anticipating and countering resistance to chemotherapy.  \nA genomic analysis comparing mutations present in pre-treated tumors with those in treatment-naive tumor genomes should identify genes associated with the emergence of resistance. Over the last decade, large-scale tumor proﬁling studies, such as Hartwig Medical Foundation (henceforth: Hartwig)3, PCAWG4, POG5, DECIDER6, GENIE7, and FH-FMI CGDB8, have provided genomic mutational landscapes of thousands of patients before and/or after treatment  \n1Institute for Research in Biomedicine(IRB Barcelona),08028Barcelona, Spain. 2Biotech Research and Innovation Centre(BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. 3Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain.  e-mail: [fran.supek@bric.ku.dk](fran.supek@bric.ku.dk)  \nwith various combinations of drugs. These genomic proﬁles, along with the clinical information, enable studies of tumor evolution during treatment and the identiﬁcation of genetic elements under increased selection upon treatment, that presumably underlie patients’ response to different chemotherapy drugs. Recently, evolutionary approaches that can assess conditional (differential) selection in cancer genomes have been developed and applied to the study of","cbCaiePibWHIsejg","https://ap.wps.com/l/cbCaiePibWHIsejg","pdf",3713060,"English","# Background\n## Why chemotherapy resistance emerges\n# Data and challenges\n## Background mutation-rate shifts across treated and untreated cohorts\n## Using non-coding DNA as a baseline\n# DiffInvex framework\n## Conditional selection across conditions\n# Applications and findings\n## Treatment-associated selected genes\n## Healthy versus cancer expansion-specific drivers\n## Additional uses across time or space","[{\"question\":\"What problem does DiffInvex address in cancer genomics?\",\"answer\":\"It quantifies conditional selection on individual genes across different conditions, handling shifts in neutral mutagenesis that complicate causal identification of chemotherapy-resistance mutations.\"},{\"question\":\"How does DiffInvex correct for changes in background mutation rates?\",\"answer\":\"It uses an empirical local mutation-rate baseline from non-coding DNA to track neutral mutagenesis changes across cancer evolution, reducing reliance on proxy covariates like replication timing or gene expression.\"},{\"question\":\"What does the study find when DiffInvex is applied to whole-genome sequences?\",\"answer\":\"It identifies treatment-associated selection in 11 genes across different chemotherapy classes, links selected mutations in specific genes with drug exposure, and supports associations using pre- versus post-therapy functional impacts replicated in independent studies.\"}]","DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy | PDF",1790161148,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18cfeabe8a4c8631ea8887537dd34849.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b943eae61ad4d4daf5dc35097f6f342.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce8ab088150ed8f2d5c342852322be2c.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd5699994a5c70091d789b9633624234.webp",980,1301]